In vitro re-challenge of CAR T cells.
Methods Cell Biol
; 183: 335-353, 2024.
Article
em En
| MEDLINE
| ID: mdl-38548418
ABSTRACT
Chimeric antigen receptor (CAR) T cells (CAR T) have emerged as a potential therapy for cancer patients. CAR T cells are capable of recognizing membrane proteins on cancer cells which initiates a downstream signaling in T cells that ends in cancer cell death. Continuous antigen exposure over time, activation of inhibitory signaling pathways and/or chronic inflammation can lead to CAR T cell exhaustion. In this context, the design of CARs can have a great impact on the functionality of CAR T cells, on their potency and exhaustion. Here, using CD19CAR as model, we provide a re-challenge protocol where CAR T cells are cultured weekly with malignant lymphoid cell lines BL-41 and Nalm-6 to simulate them with continuous antigen pressure over a four-week period. This protocol can be value for assessing CAR T cell functionality and for the comparison of different CAR constructs.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Linfócitos T
/
Transdução de Sinais
Limite:
Humans
Idioma:
En
Revista:
Methods Cell Biol
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Noruega